

STANOZOLOL

STANOZOLOL USP 10 mg

Presented as 10mg capsules in blister packs of 15 capsules - 6 blisters per box (90 capsules)

DESCRIPTION

Stanozolol is an oral androgen, a derivative of Dihydrotestosterone (DHT).

Stanozolol was originally developed to treat hereditary angioedema. As with most Androgens Stanozolol will help to create a state of anabolism and contribute to a significant increase in muscle tissue. Structurally, stanozolol is not capable of converting into estrogens therefore will not contribute to water retention which may be the case with other androgens. Also unlike most anabolic steroids, is not esterified. The drug has a large oral bioavailability, due to a C17 α -alkylation which allows the hormone to survive first pass liver metabolism when ingested.

CLINICAL PHARMACOLOGY

Anabolic steroids such as Stanozolol are synthetic derivatives of testosterone. Stanozolol has been found to increase low-density lipoproteins and decrease high-density lipoproteins. These changes are not associated with any increase in total cholesterol or triglyceride levels and revert to normal on discontinuation of treatment.

Hereditary angioedema (HAE) is an autosomal dominant disorder caused by a deficient or nonfunctional C1 esterase inhibitor (C1 INH) and clinically characterized by episodes of swelling of the face, extremities, genitalia, bowel wall, and upper respiratory tract. In small clinical studies, Stanozolol was effective in controlling the frequency and severity of attacks of angioedema and in increasing serum levels of C1 INH and C4.

PRECAUTIONS

General: Anabolic steroids may cause suppression of clotting factors II, V, VII and X and an increase in prothrombin time. Women should be observed for signs of virilization (deepening of the voice, hirsutism, acne, and clitoromegaly). To prevent irreversible change, drug therapy must be discontinued, or the dosage significantly reduced when mild virilism is first detected. Such virilization is usual following androgenic anabolic steroid use of high doses. Some virilizing changes women are irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens. Menstrual irregularities may also occur. Oral hypoglycemic dosage may need adjustment in diabetic patients who receive anabolic steroids.

DRUG INTERACTIONS

STANOZOLOL may increase sensitivity to anticoagulants; therefore, dosage of anticoagulants may have to be decreased in order to maintain the prothrombin time at the desired therapeutic level.

PRESENTATION

10mg capsules in blister packs of 15 capsules - 6 blisters per box (90 capsules)

STORAGE

Store below 25°C. Store in the original package